4//SEC Filing
Crockett Thomas Andrew 4
Accession 0001209191-23-046820
CIK 0001348911other
Filed
Aug 20, 8:00 PM ET
Accepted
Aug 21, 8:05 PM ET
Size
15.5 KB
Accession
0001209191-23-046820
Insider Transaction Report
Form 4
Crockett Thomas Andrew
DirectorPresident and CEO
Transactions
- Exercise/Conversion
Common Stock
2023-08-17+33,582→ 161,632 total - Sale
Common Stock
2023-08-18$10.73/sh−14,876$159,602→ 146,756 total - Exercise/Conversion
Restricted Stock Unit
2023-08-17−6,944→ 62,501 total→ Common Stock (6,944 underlying) - Exercise/Conversion
Restricted Stock Unit
2023-08-17−5,805→ 63,855 total→ Common Stock (5,805 underlying) - Exercise/Conversion
Performance Stock Unit
2023-08-17−20,833→ 0 total→ Common Stock (20,833 underlying)
Footnotes (7)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
- [F2]The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs and performance stock units ("PSUs"). The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.7280 to $10.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
- [F4]1/12th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on November 17, 2022, for a period of three years, subject to continued service through each vesting date.
- [F5]1/16th of the total RSUs subject to the Award shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, subject to continued service through each vesting date.
- [F6]Each PSU represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
- [F7]Shares earned upon the vesting of a percentage of the PSUs granted to the Reporting Person on June 8, 2023. Each PSU represents a contingent right to receive one share of Issuer common stock upon the Issuer's achievement of Performance Data and Enrollment Metrics goals ("Performance Metrics"). 1/4th of the total number of shares subject to the PSU shall vest on each quarterly anniversary of the Vesting Commencement Date of August 17, 2023, upon Performance Metrics achieved, subject to continued service through each vesting date.
Documents
Issuer
KalVista Pharmaceuticals, Inc.
CIK 0001348911
Entity typeother
Related Parties
1- filerCIK 0001690920
Filing Metadata
- Form type
- 4
- Filed
- Aug 20, 8:00 PM ET
- Accepted
- Aug 21, 8:05 PM ET
- Size
- 15.5 KB